Login / Signup

Impact of filgotinib on pain control in the phase 3 FINCH studies.

Peter C TaylorArthur KavanaughPeter NashJanet E PopeGeorg PongratzBruno FautrelRieke E AltenKen HasegawaShangbang RaoDick de VriesPieter-Jan StiersChris WatsonRené Westhovens
Published in: RMD open (2024)
In all RA populations studied, pain improvements occurred from week 2 and were sustained over time. In FINCH 1, filgotinib 100 mg provided similar pain amelioration to adalimumab, whereas filgotinib 200 mg resulted in greater pain improvement and higher proportion of patients with residual pain ≤10 or ≤20 mm and meeting DAS28-CRP remission criteria.
Keyphrases
  • chronic pain
  • pain management
  • neuropathic pain
  • randomized controlled trial
  • spinal cord
  • clinical trial
  • spinal cord injury
  • systemic lupus erythematosus
  • study protocol
  • double blind
  • case control
  • solid state